News

  1. FDA Approval For High Potency Fill Line 4/19/2023

    Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce that the United States Food and Drug Administration (FDA) has approved the company's high potency vial line to manufacture a commercial product.

  2. Crystal Pharmatech's CDMO Business Unit - Crystal Formulation Services Received China Drug Product Manufacturing License, Achieving The Important Milestone In Formulation Capability 4/19/2023

    Crystal Formulation Services, a subsidiary of Crystal Pharmatech, has achieved an exciting new milestone in its formulation capabilities. The company was recently granted the "Drug Manufacturing License" (C Certificate) by the Jiangsu Medical Products Administration, a branch of the Chinese National Medical Products Administration (NMPA).

  3. Berkshire Sterile Adds Non-Destructive Weight Checks To Their Low-Loss Fill Line 4/12/2023

    Berkshire Sterile Manufacturing (BSM), a fill finish CDMO located in Lee, MA, recently purchased a high precision load cell to perform non-destructive weight checks as part of their low loss fill process. The load cell is a Mettler Toledo WMF Series balance featuring unique capabilities to auto adjust for the environment and take highly accurate measurements in turbulent or highly unstable settings.

  4. Nutriband With Kindeva Drug Delivery Select Aversa Fentanyl Abuse Deterrent Formulation For Commercial Scale Manufacturing Process Development 4/4/2023

    Nutriband Inc. with Kindeva Drug Delivery (“Kindeva”) have selected the target AVERSA formulation to take forward into commercial scale manufacturing process development for the Company’s patented lead product, AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal system.

  5. Bridgewest Group Launches NovaCina, New Sterile Injectable CDMO 4/4/2023

    Global private investment firm, Bridgewest Group, recognized for developing innovative companies in life sciences, software, and deep tech, launches new Contract Development and Manufacturing Organization (CDMO) focused on sterile injectable drug products. This follows the recent announcement on the acquisition of the Perth sterile injectable manufacturing plant from Pfizer.

  6. Harm Reduction Therapeutics And Catalent Sign Commercial Supply Agreement For Naloxone Nasal Spray To Reverse Opioid Overdoses 3/23/2023

    Harm Reduction Therapeutics, a 501(c)(3) non-profit pharmaceutical company whose mission is to prevent opioid overdose deaths by making low-cost naloxone available to everyone, and Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, today announced the signing of a commercial supply agreement.

  7. Scaling Up Capacity, Eitan Medical Opens New Manufacturing Facility Bolstered by Semi-Automated Production Lines 3/22/2023

    Eitan Medical, a global leader in advanced infusion therapy and drug delivery solutions across the care continuum, announced today the opening of its new manufacturing facility at the company’s headquarters. On-site manufacturing will support Eitan Medical’s production scale of its Pharmaceutical Solutions division.

  8. Societal CDMO Announces U.S. FDA Approval For Manufacturing Of Commercial Tablet At Gainesville, Georgia Site 3/20/2023

    Societal CDMO, Inc. (“Societal CDMO” or “Societal”; NASD: SCTL), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the United States Food and Drug Administration (FDA) has approved the company as a manufacturer of a commercial tablet product.

  9. Stevanato Group Collaborates With Recipharm To Develop And Manufacture Pre-Fillable Syringes For Use In A New Soft Mist Inhaler For The Inhalation Of Sensitive Biological Products 3/16/2023

    The new strategic collaboration aims to provide innovative primary packaging to pharmaceutical and biopharmaceutical companies using Recipharm’s proprietary soft mist inhalers.

  10. Catalent And Bhami Research Laboratory Enter Into Licensing Agreement For Technology To Deliver High-Concentration Biologics Subcutaneously 3/16/2023

    Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, and Bhami Research Laboratory (BRL), today announced a licensing agreement that will provide Catalent with access to BRL’s formulation technology to help enable the subcutaneous delivery of high-concentration biologic therapies.